Hereditary Angioedema MarketSize, Share & Industry Analysis, 2026-2034By TypeBy ApplicationBy Treatment TypeBy Route of AdministrationBy End User

Hereditary angioedema therapeutics are the prescription drug products used to prevent and treat acute swelling attacks caused by hereditary angioedema, delivered as intravenous or subcutaneous biologics or, increasingly, as oral medicines. Buyers are prescribing physicians, hospital and specialty pharmacies, and the patients and caregivers who administer maintenance or on-demand doses, working within health systems and payers that determine which therapies are reimbursed.

Growth of 7.27% a year carries the global hereditary angioedema market from USD 3.75 billion in 2025 to USD 7.15 billion in 2034. The full series behind that rate covers USD 2.5 billion in 2020, USD 3.47 billion in 2024, USD 4.08 billion in 2026 and USD 5.53 billion in 2030, with 2025 as the base year.

On the type axis, growth rates run from 5.15% for C1 Esterase Inhibitor up to 10.93% for Kallikrein Inhibitor. C1 Esterase Inhibitor carries the volume: USD 2.34 billion and 62.4% of revenue in 2025, USD 3.72 billion and 52.03% in 2034. The lines gaining share are Kallikrein Inhibitor, Selective Bradykinin B2 Receptor Antagonist and Others. C1 Esterase Inhibitor lose share without losing revenue.

Cut by application, the largest line is Hospital Pharmacies: 46.93% of 2025 revenue, worth USD 1.76 billion, and 41.96% at USD 3 billion by 2034. Online Pharmacies grows faster at 12.22% against 6.1%, moving from 14.93% of revenue to 22.1% by 2034. Both this axis and the type one divide the same revenue, which is why they are alternative views rather than components.

USD 1.88 billion of 2025 revenue is generated in North America, 50.21% of the global total and the largest regional share; it reaches USD 3.36 billion by 2034. Europe is next at 27.29% and USD 1.02 billion, and Middle East and Africa last at 3.36%. Asia Pacific, Latin America and Middle East and Africa gain share across the period, so growth is not distributed evenly between regions.

Behind these figures sit five regions, four type lines and five segmentation axes, each reported for every year from 2020 to 2034. The headline 2025 value is triangulated from published sources and category proxies rather than an independently sourced count, and the same applies to the segment, regional and country breakdowns drawn from it.

• The global hereditary angioedema market moves from USD 2.5 billion in 2020 to USD 3.75 billion in 2025 and USD 7.15 billion by 2034, the forecast period compounding at 7.27% a year.
• The largest line by type is C1 Esterase Inhibitor, worth USD 2.34 billion and 62.4% of revenue in 2025, rising to USD 3.72 billion and 52.03% by 2034.
• Kallikrein Inhibitor is the fastest-growing line at 10.93%, lifting its share from 17.6% in 2025 to 24.06% in 2034 and its revenue from USD 0.66 billion to USD 1.72 billion.
• Against a base case of USD 7.15 billion in 2034, the study also reports a bear case at USD 6.08 billion and a bull case at USD 8.22 billion, with the assumptions behind each set out separately.
• 50.21% of 2025 revenue is generated in North America, worth USD 1.88 billion and rising to USD 3.36 billion by 2034; Middle East and Africa is smallest at 3.36%.
• The United States accounts for 89.89% of North America in the base year, worth USD 1.69 billion in 2025 and reaching USD 3.02 billion by 2034, the worked country example carried through that region's chapters.
• Fifteen years are reported, 2020 to 2034 with 2025 as the base: revenue, share and growth rate per line, per axis and per region rather than a single blended series.

Three movements define the forecast period in the global hereditary angioedema market: how the type mix changes, where regional weight shifts, and the rate at which the total compounds.

Not one of them points downward. Growth is everywhere in absolute terms, and the interest is entirely in where it lands.

Composition shifts on the type axis. Kallikrein Inhibitor grows at 10.93% across 2026-2034 against 5.15% for C1 Esterase Inhibitor, the widest spread on the type axis. Shares follow: 17.6% to 24.06% for Kallikrein Inhibitor, 62.4% to 52.03% for C1 Esterase Inhibitor. Neither contracts: USD 0.66 billion becomes USD 1.72 billion, USD 2.34 billion becomes USD 3.72 billion. What the spread decides is which of them a supplier's revenue is exposed to.

Asia Pacific, Latin America and Middle East and Africa gain regional share. Asia Pacific moves from 14.79% of revenue in 2025 to 18% in 2034, worth USD 0.56 billion rising to USD 1.29 billion; Latin America moves from 4.36% of revenue in 2025 to 5% in 2034, worth USD 0.16 billion rising to USD 0.36 billion; Middle East and Africa moves from 3.36% of revenue in 2025 to 4% in 2034, worth USD 0.13 billion rising to USD 0.28 billion. Against that, North America at 50.21% moving to 47%, Europe at 27.29% moving to 26%, a fall in share, not in revenue. That makes the regional split worth reading rather than scaling from the global rate: the same market rate produces different outcomes depending on where a supplier's revenue sits.

Growth compounds at 7.27% without a step change. Fifteen years of revenue run USD 2.5 billion in 2020, USD 3.47 billion in 2024, USD 3.75 billion in 2025, USD 4.08 billion in 2026, USD 5.53 billion in 2030 and USD 7.15 billion in 2034. Against 8.45% through the historical period, the 7.27% forecast rate is a continuation; no year in the series interrupts it. The risk in the number sits in the mix assumptions rather than in whether the market grows at all, which is where the type and regional sections come in.

Growth is concentrated in Kallikrein Inhibitor

The 7.27% forecast rate rests on three things that can be measured separately: the size of the existing base, the mix shift on the type axis, and where regional growth is concentrated.

The bear case and what drives it

Where the forecast could be beaten

The total depends on a single line

In North America, 50.21% of global revenue puts 2025 at USD 1.88 billion on the way to USD 3.36 billion by 2034. By revenue it sits first across the study, and the ranking does not change between 2025 and 2034.

Its share moves to 47% by 2034, a shift in share rather than in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.

Within the region the type split tracks the global one; 62.4% of 2025 revenue in C1 Esterase Inhibitor, fastest growth of 10.93% in Kallikrein Inhibitor. Revenue for North America is broken out by every segmentation axis and by country in the full report.

The largest single market in North America is the United States, at USD 1.69 billion in 2025 and USD 3.02 billion in 2034. Carrying 89.89% of the region in the base year, it sets North America's direction rather than contributing to it. Set against USD 1.88 billion and USD 3.36 billion for the region, it is why this market rather than a smaller one is the one reported in full.

the United States buys along the same lines as the market globally; C1 Esterase Inhibitor first at 62.4% of 2025 revenue and 52.03% in 2034, Kallikrein Inhibitor fastest at 10.93% on a share moving from 17.6% to 24.06%. Because the country carries 89.89% of North America, a movement in its own mix shows up in the regional totals rather than being averaged away by neighbouring markets. Per-type revenue for the United States appears on its own in the full report.

In the United States, therapies for hereditary angioedema are regulated by the Food and Drug Administration, primarily through its Center for Drug Evaluation and Research for small-molecule agents and its Center for Biologics Evaluation and Research for plasma-derived and recombinant biologic therapies. A manufacturer must secure marketing approval through either a New Drug Application or a Biologics License Application, supported by clinical evidence of safety and efficacy. Many hereditary angioedema treatments qualify for orphan drug designation, which affects review pathways and exclusivity. Manufacturing must conform to current Good Manufacturing Practice standards, and product labeling must meet FDA prescribing information requirements, including boxed warnings where clinically warranted.

In the United States the field is Pharming Group NV, Shire plc, CSL Limited, iBio Inc., BioCryst Pharmaceuticals, Others, Takeda Pharmaceutical Company Limited, KalVista Pharmaceuticals, Ionis Pharmaceuticals, Pharvaris N.V. and Astria Therapeutics. Volume sits in C1 Esterase Inhibitor at 62.4% of 2025 revenue; movement sits in Kallikrein Inhibitor at 10.93% growth. Country-level positioning and shares for each of these companies are part of the full report rather than this summary.

5.07% of global revenue is generated in Canada; USD 0.19 billion in 2025, reaching USD 0.34 billion in 2034, and 10.11% of North America.

In Europe, 27.29% of global revenue puts 2025 at USD 1.02 billion with USD 1.86 billion projected for 2034. Among the five regions it ranks second by revenue in both years.

Share settles at 26% in 2034, though revenue still rises throughout; what changes is the region's weight against faster-growing ones, which is not the same as weakening demand.

The type mix reported at global level applies here, with C1 Esterase Inhibitor the largest line at 62.4% of 2025 revenue and Kallikrein Inhibitor the fastest-growing at 10.93%. Revenue for Europe is broken out by every segmentation axis and by country in the full report.

The largest single market in Europe is Germany, at USD 0.33 billion in 2025 and USD 0.6 billion in 2034. Its 32.35% of base-year regional revenue leads the region, though enough sits elsewhere that Europe is not a proxy for it. Against regional totals of USD 1.02 billion in 2025 and USD 1.86 billion in 2034, it is the country the full report breaks out in detail.

Demand in Germany follows the type mix reported at global level: C1 Esterase Inhibitor is the largest line at 62.4% of 2025 revenue, moving to 52.03% by 2034, while Kallikrein Inhibitor grows fastest at 10.93% and takes its share from 17.6% to 24.06%. Because the country carries 32.35% of Europe, a movement in its own mix shows up in the regional totals rather than being averaged away by neighbouring markets. The full report reports Germany by type separately.

In Germany, medicines for hereditary angioedema fall under the European Union's centralized marketing authorization procedure administered by the European Medicines Agency, with national oversight from the Federal Institute for Drugs and Medical Devices, or BfArM, and enforcement under the German Medicines Act, the Arzneimittelgesetz. Because hereditary angioedema is a rare disease, affected products often carry orphan designation, which shapes the assessment pathway and post-authorization obligations. Suppliers must demonstrate compliance with Good Manufacturing Practice, submit a Summary of Product Characteristics, and maintain pharmacovigilance systems consistent with European Union requirements. Distribution and pricing decisions also interact with national reimbursement assessment bodies before market access is achieved.

Competition in Germany runs between the suppliers this study tracks: Pharming Group NV, Shire plc, CSL Limited, iBio Inc., BioCryst Pharmaceuticals, Others, Takeda Pharmaceutical Company Limited, KalVista Pharmaceuticals, Ionis Pharmaceuticals, Pharvaris N.V. and Astria Therapeutics. Volume sits in C1 Esterase Inhibitor at 62.4% of 2025 revenue; movement sits in Kallikrein Inhibitor at 10.93% growth.

7.2% of global revenue is generated in the United Kingdom; USD 0.27 billion in 2025, reaching USD 0.48 billion in 2034, and 26.47% of Europe.

France is sized at USD 0.2 billion in 2025, rising to USD 0.37 billion by 2034; 5.33% of global revenue and 19.61% of Europe. It is reported separately from Germany across every segmentation axis in the full report.

In Asia Pacific, 14.79% of global revenue puts 2025 at USD 0.56 billion with USD 1.29 billion projected for 2034. Among the five regions it ranks third by revenue in both years.

Share climbs to 18% by 2034, on growth above the market's own 7.27%, and with a bigger contribution to the revenue added over the period than the base-year figure suggests.

Segment composition follows the global pattern: C1 Esterase Inhibitor largest at 62.4% of 2025 revenue, Kallikrein Inhibitor fastest at 10.93%. Asia Pacific is reported axis by axis and country by country in the full study.

The largest single market in Asia Pacific is Japan, at USD 0.25 billion in 2025 and USD 0.57 billion in 2034. Its 44.64% of base-year regional revenue leads the region, though enough sits elsewhere that Asia Pacific is not a proxy for it. Regional revenue of USD 0.56 billion in 2025 and USD 1.29 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

Demand in Japan follows the type mix reported at global level: C1 Esterase Inhibitor is the largest line at 62.4% of 2025 revenue, moving to 52.03% by 2034, while Kallikrein Inhibitor grows fastest at 10.93% and takes its share from 17.6% to 24.06%. With 44.64% of Asia Pacific concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Revenue by type for Japan is reported separately in the full report.

In Japan, hereditary angioedema therapies are regulated by the Pharmaceuticals and Medical Devices Agency under the oversight of the Ministry of Health, Labour and Welfare, operating within the framework of the Pharmaceuticals and Medical Devices Act. Manufacturers must obtain marketing authorization, which requires demonstrating quality, safety, and efficacy through a formal review process, and many hereditary angioedema products qualify for orphan drug status given the rarity of the condition. Manufacturing sites must conform to Good Manufacturing Practice standards, and Good Vigilance Practice obligations apply once a product reaches the market. Labeling must be presented in Japanese and align with the approved package insert.

Competition in Japan runs between the suppliers this study tracks: Pharming Group NV, Shire plc, CSL Limited, iBio Inc., BioCryst Pharmaceuticals, Others, Takeda Pharmaceutical Company Limited, KalVista Pharmaceuticals, Ionis Pharmaceuticals, Pharvaris N.V. and Astria Therapeutics. Two different problems sit on the same axis: holding C1 Esterase Inhibitor at 62.4% of 2025 revenue, and taking Kallikrein Inhibitor while it grows at 10.93%.

4.27% of global revenue is generated in China; USD 0.16 billion in 2025, reaching USD 0.36 billion in 2034, and 28.57% of Asia Pacific.

Latin America holds 4.36% of the global hereditary angioedema market in 2025, worth USD 0.16 billion on the way to USD 0.36 billion by 2034. By revenue it sits fourth across the study, and the ranking does not change between 2025 and 2034.

5% of global revenue sits here by 2034, up from the 2025 level, because it outgrows the market's 7.27%; the revenue added here is disproportionate to where the region started.

C1 Esterase Inhibitor leads here as it does globally, at 62.4% of 2025 revenue, and Kallikrein Inhibitor again grows fastest at 10.93%. The full report breaks Latin America out along every axis and by country.

The largest single market in Latin America is Brazil, at USD 0.09 billion in 2025 and USD 0.2 billion in 2034. It accounts for 56.25% of regional revenue in the base year, the largest single share without dominating the region outright. Set against USD 0.16 billion and USD 0.36 billion for the region, it is why this market rather than a smaller one is the one reported in full.

Composition here matches the global split: the largest line is C1 Esterase Inhibitor at 62.4% of 2025 revenue, easing to 52.03% by 2034, and the fastest is Kallikrein Inhibitor at 10.93%, from 17.6% to 24.06%. Because the country carries 56.25% of Latin America, a movement in its own mix shows up in the regional totals rather than being averaged away by neighbouring markets. Brazil carries its own type breakdown in the full report.

In Brazil, hereditary angioedema medicines are regulated by the Agência Nacional de Vigilância Sanitária, known as ANVISA, which requires sanitary registration before any product may be marketed. Given the rare nature of hereditary angioedema, applicants may pursue pathways designed for rare disease and orphan drug products, which can affect the documentation and review process. Suppliers must demonstrate Good Manufacturing Practice certification, either through domestic inspection or recognition of a foreign regulatory authority's approval, and must submit clinical and quality data supporting the product's safety and efficacy. Labeling must appear in Portuguese and follow ANVISA's requirements for prescription medicines, including patient information leaflets.

The suppliers tracked in this study (Pharming Group NV, Shire plc, CSL Limited, iBio Inc., BioCryst Pharmaceuticals, Others, Takeda Pharmaceutical Company Limited, KalVista Pharmaceuticals, Ionis Pharmaceuticals, Pharvaris N.V. and Astria Therapeutics) compete in Brazil across the type lines above. The commercially relevant division is 62.4% of 2025 revenue in C1 Esterase Inhibitor, where the volume is, against 10.93% growth in Kallikrein Inhibitor, where share moves.

Mexico is sized at USD 0.05 billion in 2025, rising to USD 0.11 billion by 2034; 1.33% of global revenue and 31.25% of Latin America. It is reported separately from Brazil across every segmentation axis in the full report.

In Middle East and Africa, 3.36% of global revenue puts 2025 at USD 0.13 billion on the way to USD 0.28 billion by 2034. By revenue it sits fifth across the study, and the ranking does not change between 2025 and 2034.

4% of global revenue sits here by 2034, up from the 2025 level, at a pace above the 7.27% global rate, which is what makes this region worth reading separately rather than scaling from the total.

C1 Esterase Inhibitor leads here as it does globally, at 62.4% of 2025 revenue, and Kallikrein Inhibitor again grows fastest at 10.93%. Per-axis and per-country detail for Middle East and Africa sits in the full report.

USD 0.05 billion of Middle East and Africa's 2025 revenue is generated in Saudi Arabia, the region's largest market, reaching USD 0.11 billion by 2034. It accounts for 38.46% of regional revenue in the base year, the largest single share without dominating the region outright. Regional revenue of USD 0.13 billion in 2025 and USD 0.28 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

Saudi Arabia buys along the same lines as the market globally; C1 Esterase Inhibitor first at 62.4% of 2025 revenue and 52.03% in 2034, Kallikrein Inhibitor fastest at 10.93% on a share moving from 17.6% to 24.06%. Because the country carries 38.46% of Middle East and Africa, a movement in its own mix shows up in the regional totals rather than being averaged away by neighbouring markets. The full report reports Saudi Arabia by type separately.

In Saudi Arabia, pharmaceutical products for hereditary angioedema are regulated by the Saudi Food and Drug Authority, which oversees drug registration, import licensing, and post-market surveillance. Approval generally requires evidence of prior authorization by a recognized reference regulatory authority, alongside submission of quality, safety, and efficacy dossiers consistent with regional harmonization efforts among Gulf Cooperation Council health authorities. Suppliers must obtain a marketing authorization before distribution, demonstrate Good Manufacturing Practice compliance, and ensure labeling and packaging meet Saudi Food and Drug Authority requirements, including Arabic-language labeling and pharmacovigilance reporting obligations once the product is available in the local market.

In Saudi Arabia the field is Pharming Group NV, Shire plc, CSL Limited, iBio Inc., BioCryst Pharmaceuticals, Others, Takeda Pharmaceutical Company Limited, KalVista Pharmaceuticals, Ionis Pharmaceuticals, Pharvaris N.V. and Astria Therapeutics. Volume sits in C1 Esterase Inhibitor at 62.4% of 2025 revenue; movement sits in Kallikrein Inhibitor at 10.93% growth.

Within Middle East and Africa, South Africa accounts for 23.08% of regional revenue and 0.8% of the global total, worth USD 0.03 billion in 2025 and USD 0.07 billion by 2034.

Request this sample to see the full data tables and segment-level detail behind this analysis.

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by Type, Application, Treatment Type, Route of Administration, End User, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.